Bedoradrine Sulfate is a small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications. It was developed for intravenous administration to treat conditions like severe acute asthma exacerbations and preterm labor, but its development was not completed to the point of being a commercially available prescription medication. The directory classifies it as a under development API with a synthetic source/manufacturing origin. Other names for this substance include Bedoradrine sulphate, KUR-1246, Acetamide, N, N-dimethyl-2-(((7S)-5, 6, 7, 8-tetrahydro-7-(((2R)-2-hydroxy-2-(4-hydroxy-3-(2-hydroxyethyl)phenyl)ethyl)amino)-2-naphthalenyl)oxy)- and sulfate. Its PubChem CID is 9963056.
Bedoradrine sulfate
| CAS No | 194785-31-4 |
|---|---|
| Molecular Formula | C48H66N4O14S |
| Molecular Weight | 955.1 g/mol |
| Synonyms | 2-[[(7S)-7-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]-N,N-dimethylacetamide;sulfuric acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Bedoradrine Sulfate is a small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
The listed CAS number is 194785-31-4.
The listed molecular formula is C48H66N4O14S.
The listed molecular weight is 955.1 g/mol.
2-[[(7S)-7-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]-N,N-dimethylacetamide;sulfuric acid.
The source lists Bedoradrine sulphate, KUR-1246, Acetamide, N, N-dimethyl-2-(((7S)-5, 6, 7, 8-tetrahydro-7-(((2R)-2-hydroxy-2-(4-hydroxy-3-(2-hydroxyethyl)phenyl)ethyl)amino)-2-naphthalenyl)oxy)- and sulfate.